CERo Chairman and CEO Brian G. Atwood comments, “We continue to diligently work toward the completion of our IND package for the FDA for CER-1236. Having completed these toxicology studies, we are ...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of ...
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic maligna ...
CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort The ongoing ...
CER‑T therapy shows initial safety signals and prompts protocol expansion CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results